醫學影像暨放射科學系

獲獎紀錄 (Award):

癌症免疫治療學會(Society for Immunotherapy of Cancer)

美國放射腫瘤學會(American Society for Radiation Oncology)

台灣放射腫瘤學會會員(Taiwan Society for Therapeutic Radiology and Oncology)

學會會員 (Association):

1. 長庚青年Chang Gung Youth Award, Chang Gung University, 2010
2. 國科會吳大猷先生紀念獎Ta-You Wu Memorial Award, National Science and Technology Council, Taiwan, 2023
3. 中華民國癌症醫學會年輕研究者癌症研究傑出論文獎TOS Young Investigator Paper Award for Cancer Research, Taiwan Oncology Society, Taiwan, 2023
4. Cancer Prevention and Research Institute of Texas (CPRIT) Graduate Scholar, The University of Texas Health Science Center at Houston and The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2021-2022
5. Andrew Sowell-Wade Huggins Scholarship in Cancer Research, The University of Texas Health Science Center at Houston and The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2021-2022
6. SITC Young Investigator Award - Presidential Travel Award, 36^th Society for Immunotherapy of Cancer Annual Conference, Washington DC, USA, 2021
7. Ralph B. Arlinghaus, Ph.D. Scholarship, The University of Texas Health Science Center at Houston and The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2019-2020
8. ASTRO Best Abstract Award on Gastrointestinal Cancer Section, The 60^th Annual Meeting of American Society for Radiation Oncology, San Antonio, TX, USA, 2018
9. Excellent Paper Award, Journal of Therapeutic Radiology Oncology, 2016
10. OCC Young Investigator Award, World Congress of Oxygen Club of California, USA, 2010

專業證照(Licence)中華民國放射腫瘤科專科醫師Taiwan Board of Radiation Oncology

期刊論文 (Journal Publication) :

(近5年)

1.      Hsieh RCE, Krishnan S, Wu RC et al. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol. 2022 Jun 10;7(72):eabl9330. PMID: 30797890 (IF = 17.6, Immunology: 6/160 = 3.8%)

2.      Chen PY, Cheng NM, Lin CY, Chang KP, Lu YA, Tsai TY, Chen MF, Fang FM, Hsu CL, Hsieh RCE* (corresponding). Post-radiotherapy Response Assessment Using 18F-FDG PET/CT in Salivary Gland Carcinoma – A Multicenter Study. Clin Nucl Med. 2024 Oct 30. doi: 10.1097/RLU.0000000000005538 (IF = 10.0, Radiology, Nuclear Medicine, and Medical Imaging 5/135 = 3.7%)

3.      Hsieh RCE* (corresponding), Lee CH, Huang HC et al. Clinical and Dosimetric Results of Proton or Photon Radiotherapy for Large (>5 cm) Hepatocellular Carcinoma: A Retrospective Analysis. Int J Radiat Oncol Biol Phys. 2024 Mar 1;118(3):712-724 PMID: 37778426 (IF = 6.4, Radiology, Nuclear Medicine, and Medical Imaging :13/135 = 9.6%)

4.      Hsieh RCE, Chou YC, Hung CY et al. A multicenter retrospective analysis of patients with salivary gland carcinoma treated with postoperative radiotherapy alone or chemoradiotherapy. Radiother and Oncol. 2023 Sep 1;188:109891. PMID: 37659659 (IF = 4.9, Radiology, Nuclear Medicine, and Medical Imaging 18/135 = 13.3%)

5.      Son J, Hsieh RCE (co-first), Lin HY, et al. Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022 Nov 11;13:1027235. PMID: 36439116 (IF = 5.7, Immunology: 37/160= 23.1%)

6.      W.-H. Hsu, K. A. LaBella, Y. Lin, P. Xu, R. Lee, C.-E. Hsieh, L. Yang, A. Zhou, J. M. Blecher, C.-J. Wu, K. Lin, X. Shang, S. Jiang, D. J. Spring, Y. Xia, P. Chen, J. P. Shen, S. Kopetz, R. A. DePinho, Oncogenic KRAS drives lipo-fibrogenesis to promote angiogenesis and colon cancer progression. Cancer Discov. 2023 Sep 28. PMID: 37768068 (IF = 29.7, Oncology: 8/242 = 3.3%)

7.      Chen CH, Chin RL, Hartley GP, Lea ST, Engel BJ, Hsieh CE, et al. Novel murine glioblastoma models that reflect the immunotherapy resistance profile of human disease. Neuro Oncol. 2023 Jan 27; noad025. PMID: 36705543 (IF = 16.4, Clinical Neurology: 4/211 = 1.9%)

8.      B. Venkatesulu, P. Giridhar, L. Pujari, B. Chou, J. H. Lee, A. M. Block, R. Upadhyay, J. S. Welsh, M. M. Harkenrider, S. Krishnan, V. Verma, CE Hsieh, S. Pradhan, W. Small, A. A. Solanki, Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. Radiother and Oncol 177, 81-94 (2022). (IF = 4.9, Radiology, Nuclear Medicine, and Medical Imaging 18/135 = 13.3%)

9.      Lee CH, Chen AH, Hung SP, Hsieh CE et al. Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. Cancers (Basel). 2022 Mar 23;14(7):1616. PMID: 35406392 (IF = 4.5, Oncology 73/242 = 30.2%)

10.    Venkatesulu BP, Chan DP, Giridhar P, Upadhyay R, Sharma A, Elghazawy H, Elumalai T, Mallick S, Hsieh CE. A systematic review and meta-analysis of the impact of radiation-related lymphopenia on outcomes in pancreatic cancer. Future Oncol. 2022 May;18(15):1885-1895. PMID: 35132868. (IF = 3.3, Oncology 135/241 = 56.0%)

11.    Hekman L, Barrett A, Ross D, Palaganas E, Giridhar P, Elumalai T, Pragathee V, Block AM, Welsh JS, Harkenrider MM, Saini S, Roy S, Farooq A, Gupta G, Hsieh CE, Venkatesulu BP, Solanki AA. A Systematic Review of Clinical Trials Comparing Radiation Therapy Versus Radical Prostatectomy in Prostate Cancer. Clin Genitourin Cancer. 2024 Jul 11;22(5):102157. PMID: 39084158 (IF = 2.3, Oncology 178/242=73.6%)

12.    Elumalai T, Periasamy K, Rajendran I, Yedala A, Giridhar P, Upadhya R, Kim BK, Sharma A, Elghazawy H, Dhanireddy B, Mallick S, Hsieh CE, Johnny C, Venkatesulu BP. A systematic review of radiation-related lymphopenia in genito-urinary malignancies. Cancer Invest. 2021 Oct;39(9):769-776. PMID: 34313522 (IF = 2.4, Oncology 188/241 = 78.0%)

13.    Chou YC, Wu YY, Hung SP, Tsang NM, Pai PC, Jaing TH, Lin CY, Hsieh CE, Fan KH, Kao WH, Tseng CK. Treatment of Primary Central Nervous System Germinomas With Short-course Induction Chemotherapy Followed by Low-dose Radiotherapy Without a Tumor Bed Boost: Prognostic Impact of Human Chorionic Gonadotropin. J Pediatr Hematol Oncol. 2021 Oct 1;43(7):e907-e912. PMID: 33235154 (IF = 2.4, Oncology 288/241 =94.6%)

14.    Hung SP, Huang BS, Hsieh CE et al. Clinical Outcomes of Patients With Unresectable Cholangiocarcinoma Treated With Proton Beam Therapy. Am J Clin Oncol 2020; 43: 180-186. PMID: 31764017 (IF = 2.6, Oncology 175/241 = 72.6%)

15.    Cheng NM, Hsieh CE, Fang YHD et al. Development and validation of a prognostic model incorporating [18 F] FDG PET/CT radiomics for patients with minor salivary gland carcinoma, EJNMMI Res. 2020; 10: 74. PMID: 32632638 (IF = 3.2, Radiology, Nuclear Medicine, and Medical Imaging: 53/135 = 39.2%)

16.    Abousaida B, Hsieh CE (co-first), Venkatesulu BP, Krishnan S. Technological Advances in Radiotherapy. Radiotherapy of Liver Cancer. 2021, pp 73-91 (Textbook chapter; Print ISBN: 978-981-16-1814-7)

17.    S. Mallick, A. V.R, P. Giridhar, R. Upadhyay, B.-K. Kim, A. Sharma, H. Elghazawy, T. Elumalai, V. Solipuram, CE Hsieh, C. Hentz, A. A. Solanki, J. Li, D. P. Chan, E. Ness, B. P. Venkatesulu, D. R. Grosshans, A Systematic Review and Meta-analysis of the Impact of Radiation-Related Lymphopenia on Outcomes in High-Grade Gliomas. South Asian J Cancer, (2022). PMID: 36756098

18.    Venkatesulu BP, Chandrasekar VT,Girdhar P, Advani P, Sharma A, Elumalai T, Hsieh CE, Elghazawy HI, Verma V, and Krishnan S. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectrum 2021; 5, 2 PMID: 32511470

19.    Venkatesulu BP, Lester S, Hsieh CE, Verma V, Sharon E, Ahmed M, Krishnan S. Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls. JNCI Cancer Spectrum 2021; 5, 1 PMID: 3343792